Pharma BD Deal Intelligence
Acquirer and target jointly filed bankruptcy within 22 months of closing; the acquired asset was liquidated for a $450K fire-sale price.
Full analysis, sources & comparables →BioTransplant CEO Elliot Lebowitz framed the $55.3M stock deal as bringing 'complementary management and complementary technologies,' giving BioTransplant…
BioTransplant has signed a definitive agreement to acquire Eligix; the addition adds two late-stage pipeline products expected to add near-term European…
BioTransplant and its Eligix subsidiary filed Chapter 11; the Eligix HDM Cell Separation System was sold to Miltenyi Biotec for $450,000 plus 4-10% royalties —…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
6.6M BioTransplant shares for Eligix. Below $250M threshold but strategically notable: Harvard-affiliated cell-therapy/stem-cell graft purification (BCell-HDM, TCell-HDM).
Acquirer and target jointly filed bankruptcy within 22 months of closing; the acquired asset was liquidated for a $450K fire-sale price.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioTransplant Inc. / Eligix Inc. (this deal) | 2001 | $55M | 10 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals